Cargando…
The integrated single-cell analysis developed a lactate metabolism-driven signature to improve outcomes and immunotherapy in lung adenocarcinoma
BACKGROUND: It has been suggested that lactate metabolism (LM) is crucial for the development of cancer. Using integrated single-cell RNA sequencing (scRNA-seq) analysis, we built predictive models based on LM-related genes (LMRGs) to propose novel targets for the treatment of LUAD patients. METHODS...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073691/ https://www.ncbi.nlm.nih.gov/pubmed/37033259 http://dx.doi.org/10.3389/fendo.2023.1154410 |
_version_ | 1785019624778104832 |
---|---|
author | Zhang, Pengpeng Pei, Shengbin Gong, Zeitian Ren, Qianhe Xie, Jiaheng Liu, Hong Wang, Wei |
author_facet | Zhang, Pengpeng Pei, Shengbin Gong, Zeitian Ren, Qianhe Xie, Jiaheng Liu, Hong Wang, Wei |
author_sort | Zhang, Pengpeng |
collection | PubMed |
description | BACKGROUND: It has been suggested that lactate metabolism (LM) is crucial for the development of cancer. Using integrated single-cell RNA sequencing (scRNA-seq) analysis, we built predictive models based on LM-related genes (LMRGs) to propose novel targets for the treatment of LUAD patients. METHODS: The most significant genes for LM were identified through the use of the AUCell algorithm and correlation analysis in conjunction with scRNA-seq analysis. To build risk models with superior predictive performance, cox- and lasso-regression were utilized, and these models were validated on multiple external independent datasets. We then explored the differences in the tumor microenvironment (TME), immunotherapy, mutation landscape, and enriched pathways between different risk groups. Finally, cell experiments were conducted to verify the impact of AHSA1 in LUAD. RESULTS: A total of 590 genes that regulate LM were identified for subsequent analysis. Using cox- and lasso-regression, we constructed a 5-gene signature that can predict the prognosis of patients with LUAD. Notably, we observed differences in TME, immune cell infiltration levels, immune checkpoint levels, and mutation landscapes between different risk groups, which could have important implications for the clinical treatment of LUAD patients. CONCLUSION: Based on LMRGs, we constructed a prognostic model that can predict the efficacy of immunotherapy and provide a new direction for treating LUAD. |
format | Online Article Text |
id | pubmed-10073691 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100736912023-04-06 The integrated single-cell analysis developed a lactate metabolism-driven signature to improve outcomes and immunotherapy in lung adenocarcinoma Zhang, Pengpeng Pei, Shengbin Gong, Zeitian Ren, Qianhe Xie, Jiaheng Liu, Hong Wang, Wei Front Endocrinol (Lausanne) Endocrinology BACKGROUND: It has been suggested that lactate metabolism (LM) is crucial for the development of cancer. Using integrated single-cell RNA sequencing (scRNA-seq) analysis, we built predictive models based on LM-related genes (LMRGs) to propose novel targets for the treatment of LUAD patients. METHODS: The most significant genes for LM were identified through the use of the AUCell algorithm and correlation analysis in conjunction with scRNA-seq analysis. To build risk models with superior predictive performance, cox- and lasso-regression were utilized, and these models were validated on multiple external independent datasets. We then explored the differences in the tumor microenvironment (TME), immunotherapy, mutation landscape, and enriched pathways between different risk groups. Finally, cell experiments were conducted to verify the impact of AHSA1 in LUAD. RESULTS: A total of 590 genes that regulate LM were identified for subsequent analysis. Using cox- and lasso-regression, we constructed a 5-gene signature that can predict the prognosis of patients with LUAD. Notably, we observed differences in TME, immune cell infiltration levels, immune checkpoint levels, and mutation landscapes between different risk groups, which could have important implications for the clinical treatment of LUAD patients. CONCLUSION: Based on LMRGs, we constructed a prognostic model that can predict the efficacy of immunotherapy and provide a new direction for treating LUAD. Frontiers Media S.A. 2023-03-22 /pmc/articles/PMC10073691/ /pubmed/37033259 http://dx.doi.org/10.3389/fendo.2023.1154410 Text en Copyright © 2023 Zhang, Pei, Gong, Ren, Xie, Liu and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Zhang, Pengpeng Pei, Shengbin Gong, Zeitian Ren, Qianhe Xie, Jiaheng Liu, Hong Wang, Wei The integrated single-cell analysis developed a lactate metabolism-driven signature to improve outcomes and immunotherapy in lung adenocarcinoma |
title | The integrated single-cell analysis developed a lactate metabolism-driven signature to improve outcomes and immunotherapy in lung adenocarcinoma |
title_full | The integrated single-cell analysis developed a lactate metabolism-driven signature to improve outcomes and immunotherapy in lung adenocarcinoma |
title_fullStr | The integrated single-cell analysis developed a lactate metabolism-driven signature to improve outcomes and immunotherapy in lung adenocarcinoma |
title_full_unstemmed | The integrated single-cell analysis developed a lactate metabolism-driven signature to improve outcomes and immunotherapy in lung adenocarcinoma |
title_short | The integrated single-cell analysis developed a lactate metabolism-driven signature to improve outcomes and immunotherapy in lung adenocarcinoma |
title_sort | integrated single-cell analysis developed a lactate metabolism-driven signature to improve outcomes and immunotherapy in lung adenocarcinoma |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073691/ https://www.ncbi.nlm.nih.gov/pubmed/37033259 http://dx.doi.org/10.3389/fendo.2023.1154410 |
work_keys_str_mv | AT zhangpengpeng theintegratedsinglecellanalysisdevelopedalactatemetabolismdrivensignaturetoimproveoutcomesandimmunotherapyinlungadenocarcinoma AT peishengbin theintegratedsinglecellanalysisdevelopedalactatemetabolismdrivensignaturetoimproveoutcomesandimmunotherapyinlungadenocarcinoma AT gongzeitian theintegratedsinglecellanalysisdevelopedalactatemetabolismdrivensignaturetoimproveoutcomesandimmunotherapyinlungadenocarcinoma AT renqianhe theintegratedsinglecellanalysisdevelopedalactatemetabolismdrivensignaturetoimproveoutcomesandimmunotherapyinlungadenocarcinoma AT xiejiaheng theintegratedsinglecellanalysisdevelopedalactatemetabolismdrivensignaturetoimproveoutcomesandimmunotherapyinlungadenocarcinoma AT liuhong theintegratedsinglecellanalysisdevelopedalactatemetabolismdrivensignaturetoimproveoutcomesandimmunotherapyinlungadenocarcinoma AT wangwei theintegratedsinglecellanalysisdevelopedalactatemetabolismdrivensignaturetoimproveoutcomesandimmunotherapyinlungadenocarcinoma AT zhangpengpeng integratedsinglecellanalysisdevelopedalactatemetabolismdrivensignaturetoimproveoutcomesandimmunotherapyinlungadenocarcinoma AT peishengbin integratedsinglecellanalysisdevelopedalactatemetabolismdrivensignaturetoimproveoutcomesandimmunotherapyinlungadenocarcinoma AT gongzeitian integratedsinglecellanalysisdevelopedalactatemetabolismdrivensignaturetoimproveoutcomesandimmunotherapyinlungadenocarcinoma AT renqianhe integratedsinglecellanalysisdevelopedalactatemetabolismdrivensignaturetoimproveoutcomesandimmunotherapyinlungadenocarcinoma AT xiejiaheng integratedsinglecellanalysisdevelopedalactatemetabolismdrivensignaturetoimproveoutcomesandimmunotherapyinlungadenocarcinoma AT liuhong integratedsinglecellanalysisdevelopedalactatemetabolismdrivensignaturetoimproveoutcomesandimmunotherapyinlungadenocarcinoma AT wangwei integratedsinglecellanalysisdevelopedalactatemetabolismdrivensignaturetoimproveoutcomesandimmunotherapyinlungadenocarcinoma |